BRIEF-Eisai Co Ltd - Revenue Of Leqembi (Preliminary Basis)
Reuters
Feb 06
BRIEF-Eisai Co Ltd - Revenue Of Leqembi (Preliminary Basis)
Feb 6 (Reuters) - Eisai Co Ltd 4523.T:
EISAI CO LTD: REVENUE OF LEQEMBI (PRELIMINARY BASIS)
EISAI CO LTD: GLOBAL REVENUE (PRE-AUDIT BASIS) OF ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LEQEMBI WAS 61.8 BILLION YEN FOR THE CUMULATIVE PERIOD OF Q3 OF FY2025
Source text: ID:nTSnf8673d
Further company coverage: 4523.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.